New research seeks to improve survival for myeloma and lymphoma patients

July 25, 2012, University of York

Researchers at the University of York are launching a major study of lymphoma and myeloma aimed at promoting earlier diagnosis and improving survival for patients with these cancers, which are among the most common in the UK.

The project, which is funded by Cancer Research UK as part of the National Awareness and Early Diagnosis Initiative (NAEDI), will develop an evidence base that could be used to reduce time-to-diagnosis in patients with these types of cancers.

Led by Dr Debra Howell of the and Genetics Unit in the University's Department of , the £300,000 study is prompted by data indicating that survival for many cancers is poorer in the UK than Europe.

Dr Howell says: "The UK Improving Outcomes Guidance for cancer considers that the most important reason for this is likely to be late stage diagnosis; earlier diagnosis may increase the scope for successful treatment and could save thousands of lives.

"There are nearly 15,000 new diagnoses annually of (Hodgkin and non-Hodgkin) and in the UK, and early diagnosis is complicated by the complex nature of these diseases. The symptoms of lymphoma and myeloma can be strikingly similar to those of more common, benign conditions and this poses exacting challenges for both patients and GPs when identifying symptoms that may indicate malignancy. This situation often leads to delayed help-seeking and prevents early hospital referral."

Patients said:

"The doctors were concerned about these swollen glands in my neck which I'd had for a couple of months. I never thought anything about it because they didn't hurt."

"I just thought it was a swollen gland. It could have been an infection of the throat."

"I got the lump taken away and the doctor said I'm sorry to have to say that it's lymphoma. But prior to that I hadn't felt poorly. Nothing. I've had no symptoms. I've not been poorly at all really."

Despite UK Referral Guidance, data from the National Cancer Data Repository (2007) reported that patients with haematological malignancies, including lymphoma and myeloma, were generally more often diagnosed after emergency presentation and less often referred via the Government recommended two-week wait compared to those with other cancers.

The new study will include a cohort of around 1000 patients newly diagnosed with lymphoma or myeloma during 2012.

Its specific objectives are to:

  • interview patients to explore their symptoms before diagnosis, how they reacted to these and from whom they sought help
  • use primary care (GP) and hospital records to examine events between patients seeking help and diagnosis, such as GP appointments and hospital referrals
The evidence generated will inform UK clinical guidance and could be used to develop tools such as computer-based decision programmes to help GPs to identify patients with these cancers. This could help to promote appropriate investigation and referral, reduce time-to- and improve outcomes. Educational resources will also be produced to encourage people with possible symptoms to seek help sooner.

The study is based on the infrastructure of the Haematological Malignancy Research Network (HMRN), which was established in 2004. HMRN is a specialist population-based registry, funded by Leukaemia and Lymphoma Research (LLR), which includes all newly diagnosed with a haematological malignancy within the Yorkshire and Humber and the Yorkshire Coast Cancer Network areas – more than 2,000 new diagnoses from a population of 3.6 million each year.

Dr Howell adds: "As the HMRN area is representative of the UK as a whole in terms of both demography and clinical practice, the results could inform practice around the UK."

Explore further: Study examines number of GP visits before cancer patients are referred to specialists

Related Stories

Study examines number of GP visits before cancer patients are referred to specialists

February 23, 2012
More than three quarters (77%) of cancer patients who first present to their family doctors (GPs) with suspicious symptoms are referred to hospital after only one or two consultations, a new study has found. However, the ...

Bowel, oesophageal and pancreatic cancers show biggest improvement in diagnosis time

November 8, 2011
(Medical Xpress) -- New research shows that bowel, oesophageal and pancreatic cancers have seen the greatest improvement in the time it takes from when a patient first visits their GP with symptoms to when they are diagnosed ...

Type 2 diabetes linked to increased blood cancer risk

June 5, 2012
Patients with type 2 diabetes have a 20 percent increased risk of developing blood cancers, such as non-Hodgkin lymphoma, leukemia and myeloma, according to a new meta-analysis led by researchers at The Miriam Hospital. The ...

Computer-based tool to improve diagnosis and prognosis for cancer patients

October 31, 2011
A computer-based tool could help GPs to speed up the diagnosis and treatment of patients suffering from two of the most common forms of cancer, potentially saving thousands of lives every year.

Simple online tool to aid GPs in early ovarian cancer diagnosis

January 4, 2012
The lives of hundreds of women could be saved every year, thanks to a simple online calculator that could help GPs identify women most at risk of having ovarian cancer at a much earlier stage.

Recommended for you

Study: Cells of three advanced cancers die with drug-like compounds that reverse chemo failure

January 23, 2018
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers—ovarian, prostate and breast.

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Scientists block the siren call of two aggressive cancers

January 23, 2018
Aggressive cancers like glioblastoma and metastatic breast cancer have in common a siren call that beckons the bone marrow to send along whatever the tumors need to survive and thrive.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.